Los Angeles Capital Management LLC Has $1.55 Million Stock Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Los Angeles Capital Management LLC cut its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 21.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 366,554 shares of the biopharmaceutical company’s stock after selling 99,400 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Vanda Pharmaceuticals were worth $1,547,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its position in Vanda Pharmaceuticals by 352.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 5,186 shares in the last quarter. Raymond James & Associates acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at about $42,000. Mackenzie Financial Corp bought a new stake in Vanda Pharmaceuticals during the fourth quarter worth about $46,000. Sherbrooke Park Advisers LLC acquired a new position in Vanda Pharmaceuticals during the third quarter valued at approximately $52,000. Finally, New York State Common Retirement Fund grew its stake in Vanda Pharmaceuticals by 57.1% in the third quarter. New York State Common Retirement Fund now owns 17,805 shares of the biopharmaceutical company’s stock valued at $77,000 after purchasing an additional 6,470 shares in the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. StockNews.com downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, April 22nd. TheStreet cut shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a report on Thursday, February 8th.

Vanda Pharmaceuticals Trading Up 13.2 %

Shares of NASDAQ VNDA opened at $5.48 on Wednesday. Vanda Pharmaceuticals Inc. has a 12 month low of $3.30 and a 12 month high of $6.98. The stock has a 50 day moving average of $4.34 and a 200-day moving average of $4.10. The company has a market capitalization of $318.93 million, a P/E ratio of 109.60 and a beta of 0.71.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The firm had revenue of $45.27 million for the quarter, compared to the consensus estimate of $37.00 million. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. Analysts predict that Vanda Pharmaceuticals Inc. will post -0.06 EPS for the current fiscal year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.